Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Report: Melinta Therapeutics, Inc - Strategic SWOT Analysis Review


Print article Print article
2014-03-28 12:27:52 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Melinta Therapeutics, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

* Business description - A detailed description of the company's operations and business divisions.
* Corporate strategy - GlobalData's summarization of the company's business strategy.
* SWOT analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
* Company history - Progression of key events associated with the company.

* Major products and services - A list of major products, services and brands of the company.
* Key competitors - A list of key competitors to the company.
* Key employees - A list of the key executives of the company.
* Executive biographies - A brief summary of the executives' employment history.
* Key operational heads - A list of personnel heading key departments/functions.
* Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
* Key manufacturing facilities - A list of key manufacturing facilities of the company.

Full Report Details at
- www.fastmr.com/prod/781002_melinta_therapeutics_inc_strategic_sw ..

Highlights

Melinta Therapeutics, Inc. (Melinta) formerly Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development of novel antibiotics. Its drugs are intended to treat the various bacterial infections. The company's lead product is an investigational antibiotic, delafloxacin. The Phase III drug candidate is in development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. Other products in the pipeline include radezolid and next generation macrolides among others. The products are based on its ribosome crystallography platform, engineered to overcome the problem of drug resistance.

Melinta Therapeutics, Inc Key Recent Developments

Oct 07, 2013: Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals
Oct 07, 2013: Melinta Therapeutics Expands Leadership Team with Appointment of Lyn Baranowski as SVP of Corporate Development and Strategy
Apr 03, 2013: Rib-X Appoints Mary Szela As CEO
Jan 04, 2013: Rib-X Pharma Appoints Mary Szela As New Chairman Of Board Of Directors

Reasons to Get this Report

* Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
* Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
* Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
* Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Melinta Therapeutics, Inc - Key Facts
Melinta Therapeutics, Inc - Key Employees
Melinta Therapeutics, Inc - Key Employee Biographies
Melinta Therapeutics, Inc - Major Products and Services
Melinta Therapeutics, Inc - Pharmaceutical Pipeline Products Data
Melinta Therapeutics, Inc, Pipeline Products by Therapy Area
Melinta Therapeutics, Inc, Pipeline Products by Development Phase
Melinta Therapeutics, Inc - History
Melinta Therapeutics, Inc - Company Statement
Melinta Therapeutics, Inc - Locations And Subsidiaries
Head Office
Section 2 - Company Analysis
Melinta Therapeutics, Inc - Business Description
Melinta Therapeutics, Inc - Corporate Strategy
Melinta Therapeutics, Inc - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics, Inc - Strengths
Strength - Proprietary Technology
Strength - Agreements & Collaborations
Strength - Expertise In-house Research Activities
Melinta Therapeutics, Inc - Weaknesses
Weakness - Lack of Product Revenue
Weakness - Lack of Capital Resources
Melinta Therapeutics, Inc - Opportunities
Opportunity - Pipeline Portfolio
Opportunity - Growing Market Opportunities in Emerging Markets
Opportunity - Market Potential: Antibiotics
Opportunity - Qualified Infectious Disease Product Designation
Melinta Therapeutics, Inc - Threats
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Tough Credit Market Conditions
Melinta Therapeutics, Inc - Key Competitors
Section 3 - Company's Lifesciences Financial Deals and Alliances
Melinta Therapeutics, Inc, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Melinta Therapeutics, Inc, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Melinta Therapeutics, Inc, Recent Deals Summary
Section 4 - Company's Recent Developments
Melinta Therapeutics, Inc, Recent Developments
Oct 07, 2013: Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals
Oct 07, 2013: Melinta Therapeutics Expands Leadership Team with Appointment of Lyn Baranowski as SVP of Corporate Development and Strategy
Apr 03, 2013: Rib-X Appoints Mary Szela As CEO

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=781002&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com